Adicet Bio reported early human data for its donor-derived, off-the-shelf CAR-T approach prula-cel in lupus nephritis, including kidney response outcomes after roughly a year of follow-up. The company said 50% of evaluable patients achieved a complete kidney response, with 54% meeting a widely used remission criterion, and it noted no serious cytokine release syndrome cases or neurological side effects in the update.